Red clover vs soy isoflavones is a comparison between two different sets of molecules, not two grades of the same ingredient. The two plants carry different isoflavones, so a specification written for one does not describe the other, and the labeling basis that applies to each is different as well.
Red clover (Trifolium pratense L.) is a legume whose aerial parts carry a set of isoflavones that has been traded as a standardized extract for decades. This article sets out which molecules those are, how they differ from the soy set, what has to be stated on a specification, and what regulators have actually concluded about safety and about claims.
Does Red Clover Contain Isoflavones?
Yes. Red clover contains isoflavones, and the European Food Safety Authority names it directly as one of the sources its isoflavone assessment covers. The commercially relevant question is not whether they are present but which of the four the material is standardized on, because that choice decides what a certificate of analysis can report.
-
The four isoflavones red clover material is standardized on
Our own product page lists the HPLC markers for the red clover isoflavones powder we supply as formononetin, biochanin A, daidzein and genistein, with formononetin the highest of the four. Health Canada's monograph for red clover isoflavone extract names the same four as the specific isoflavones a label may declare next to the total. The two principal markers are the part that matters, because neither of them is the pair a soy specification is built on.
-
Where the isoflavones sit in the plant
Red clover isoflavones are taken from the aerial parts. Our product page states the plant part as dried flowering stems, leaves and inflorescence, and the INCI name as Trifolium pratense (Clover) Flower Extract. Material described as coming from roots or rhizomes is a different raw material from the one this isoflavone profile is built on, and the plant part belongs in the specification rather than in a footnote.
Red Clover vs Soy Isoflavones: Two Different Molecules, Two Profiles
Red clover vs soy isoflavones is not a comparison of two suppliers' versions of one ingredient. The two plants carry different molecules, so the two materials are standardized on different markers, released against different certificates, and labeled on a basis that has to be stated separately.
-
What the European assessment says about both sources
The European Food Safety Authority's 2015 opinion on isoflavones in food supplements states that isoflavones can be found in, among other sources, soy, red clover and kudzu root, and lists the main isoflavones across those sources as genistein, daidzein, glycitein, formononetin, biochanin A and puerarin. Within the same document, the literature the authority cites describes purified soy isoflavones as genistein, daidzein and glycitein. Red clover material is standardized on formononetin and biochanin A instead, with daidzein and genistein present as markers below those two.
-
Why a specification written for one does not describe the other
A purchase order for "isoflavones 20%" does not say which molecules are being bought. A red clover lot released against a formononetin and biochanin A profile is not a substitute for a soy lot released against genistein and daidzein, and a formulation built on one marker set cannot be moved to the other without redoing the dose basis and the label. They are two specifications, not two prices for one specification.
| Line | Red clover (Trifolium pratense) | Soy (Glycine max) | What it changes at purchase |
| Principal markers the material is standardized on | Formononetin, biochanin A | Genistein, daidzein | Different markers mean different assays and different certificates of analysis |
| Further aglycones in the group | Daidzein and genistein, below the two principal markers in our material | Glycitein | A soy-style marker list does not describe a red clover lot |
| Glycoside forms that have to be converted | Biochanin A-7-O-glucoside, formononetin-7-O-glucoside, daidzin, genistin | Genistin, daidzin and their malonyl and acetyl conjugates | Conversion to aglycone equivalents is not one to one, so the sum you quote depends on the basis |
| Authorized health claim in the European Union | None | None | A claim has to come from another ingredient in the formula, if it comes at all |
-
Why comparing the price per kilo of "isoflavones" fails
Two quotations can both read "20% isoflavones" and still describe different products, because the figure does not say which molecules are counted or whether the count is on an aglycone basis. A buyer comparing red clover vs soy isoflavones on price per kilo is therefore comparing one marker set against a different marker set. The comparison only becomes meaningful once the specification names the markers and the basis, which is the subject of the next section.
What "Total Isoflavones" Means on a Specification: The AIE Basis
A figure such as 20% total isoflavones is not a complete specification, because the number changes depending on whether the glycosides are counted at full weight or converted first. Canada's regulator states the basis that has to be used, and the gap between the two methods approaches a factor of two.
-
Aglycones, glycosides, and why adding them together overstates the figure
Health Canada's monograph for red clover isoflavone extract defines aglycone isoflavone equivalents as the maximum amount of bioavailable isoflavone after ingestion, and explains that glycoside forms must first be cleaved to the aglycone form before they can be absorbed. It states that simple addition of aglycone and glycoside forms will overestimate the bioavailable quantity by almost a factor of two. That is not a rounding difference. It is the difference between a label that can be defended and one that cannot.
-
The conversion factors the monograph sets out
The monograph gives the factor for each form. Aglycones count at full weight; the common glycosides and their malonyl conjugates count at roughly one half to two thirds of their weight, which is why a sum of raw peak areas is not the figure a label needs.
| Isoflavone form | Factor to total AIE | Where it appears |
| Biochanin A, formononetin, genistein, daidzein, glycitein | 1.0 | Aglycones, counted at full weight |
| Biochanin A-7-O-glucoside | 0.64 | Red clover glycoside |
| Formononetin-7-O-glucoside | 0.62 | Red clover glycoside |
| Genistin | 0.625 | Glycoside |
| Daidzin | 0.611 | Glycoside |
| Malonyl genistin | 0.521 | Malonyl conjugate |
| Malonyl daidzin | 0.506 | Malonyl conjugate |
-
What to ask a supplier before you compare two quotations
Three questions settle it. Is the percentage expressed on a total aglycone equivalent basis or as a sum of peak areas? Is it stated on an as-is basis or on a dried basis? And does the certificate of analysis report the individual markers or only the total? A supplier who can answer all three from the same document is quoting against a specification rather than a round number, and the two quotations become comparable only at that point.
Red Clover Isoflavones Side Effects: What the Regulators Actually Say
Red clover isoflavones side effects is a question with a documented answer, and it is more specific than most product pages suggest. Two regulators have published the relevant text: the European Food Safety Authority on safety, and Health Canada on the contraindications and adverse reactions a label has to carry.
-
What the European safety assessment concluded
EFSA's panel on food additives and nutrient sources assessed whether isoflavones from food supplements are associated with harmful effects on the mammary gland, the uterus and the thyroid in peri- and post-menopausal women. Its summary records that the human data did not support a hypothesis of increased breast cancer risk from observational studies, and showed no effect on mammographic density, and no effect on the proliferation marker Ki-67 in intervention studies. No effect was found on endometrial thickness or on histopathological changes in the uterus up to 30 months of supplementation at 150 mg per day of soy isoflavones, and thyroid hormone levels were not changed.
-
Where that conclusion stops
The same summary records its own limits. After 60 months, some non-malignant histopathological changes were reported. The panel concluded that it was not possible to derive a single health-based guidance value for the different preparations, and that the doses and durations used in the intervention studies could serve as guidance instead. The supplements the assessment covers typically provide 35 to 150 mg of isoflavones per day. The background intake from the general European diet was estimated below 1 mg per day.
-
The contraindication in the Canadian monograph
Health Canada's monograph carries a contraindication in direct terms: do not use if you have or have had breast cancer or tumors, or a predisposition to breast cancer indicated by an abnormal mammogram or biopsy, or a family member with breast cancer. That is a regulatory restriction rather than a marketing caution, and for a product aimed at a general consumer audience it is the single most important line on the label.
-
Cautions that apply before starting
The same monograph lists the cautions. Users who are not up to date on mammograms and gynecological evaluations should consult a health care practitioner before use, as should anyone with a history of hormonal or gynecological disease, anyone taking hormone replacement therapy, and anyone whose symptoms worsen. Use beyond one year should be discussed with a practitioner, and the monograph notes that the bone mineral density use requires at least six months before an effect would be expected, and the menopausal symptom use at least eight weeks.
-
Known adverse reactions to act on
The monograph names the reactions that should stop use: new symptoms such as breast pain, a recurrence of menstruation, or uterine spotting. Those are the events a consumer leaflet has to carry, and they are also the answer a supplier can give when a customer asks whether the ingredient comes with a safety statement.
This section reports what two regulators have published. It is not medical advice, and it makes no claim on our own account about what red clover isoflavones do.
Red Clover Extract Powder: Grades Traded and How They Are Specified
Red clover extract powder is traded at several standardization levels, and the grade is only half of what has to be specified. The percentage says how much isoflavone is present; the certificate has to say which markers, on which basis, and with which limits on everything else.
-
The grades and the markers behind them
Our product page lists red clover isoflavones powder at 8%, 10%, 20% and 40% total isoflavones by HPLC, with 20% and 40% as the two grades most commonly bought in bulk. The same page names the HPLC markers as formononetin, biochanin A, daidzein and genistein. A grade is therefore a concentration plus a marker set, and the two travel together: changing the marker set changes the product even when the percentage stays the same.
-
The lines that decide a release
Beyond the assay figure, the specification carries the physical and elemental limits. Our published values are a brown fine powder with a characteristic herbal odor, solubility in hydro-alcoholic solution with limited solubility in water, 80 mesh particle size, loss on drying at or below 5.0%, ash at or below 5.0%, lead at or below 3 ppm and arsenic at or below 2 ppm. The microbiological lines are a total plate count at or below 10,000 cfu/g, yeast and mold at or below 1,000 cfu/g, E. coli negative and Salmonella absent.
-
Packaging, shelf life and order size
Our product page states a 24-month shelf life and offers 25 kg fiber drums with double PE inner bags or 1 kg foil bags, with a minimum order of 1 kg. For a formulator the container is part of the specification rather than a shipping detail, because the loss on drying limit is set at delivery and the container is what preserves it.
Are Health Claims for Red Clover Isoflavones Allowed?
The short answer is that no claim has been authorized for red clover isoflavones in the European Union, and the position in the United States is narrower than a raw material page usually implies. Which statement can appear on a finished pack therefore depends on the market and on what else is in the formula.
-
The European position
The European Food Safety Authority assessed two claims for soy isoflavones under Article 13 of Regulation (EC) No 1924/2006: maintenance of bone mineral density, and reduction of vasomotor symptoms associated with menopause. Its 2012 opinion concluded that the evidence provided was insufficient to establish a cause and effect relationship for either. The list of authorized claims in Commission Regulation (EU) No 432/2012 contains no entry for isoflavones or for red clover, so a claim on a European pack cannot rest on the isoflavones themselves.
-
The United States position
In the United States the same raw material appears in the FDA food substances database as clover tops, red, extract solid, for use as a flavoring agent or adjuvant, under 21 CFR 182.20, with FEMA number 2326. That is a flavoring use, and it is not the same thing as a route to an isoflavone claim on a supplement label. A structure or function statement on a dietary supplement is a separate pathway with its own requirements and its own disclaimer.
-
Canada as the clearest template
Canada is the market where the rules for this ingredient are written down most completely. The Health Canada monograph permits two conditional uses: it may reduce severe and frequent menopausal symptoms such as hot flashes and night sweats, and it helps attenuate bone mineral density loss in postmenopausal women when used in conjunction with adequate amounts of calcium and vitamin D. The same monograph sets the daily dose at 40 to 100 mg total aglycone isoflavone equivalents. Where a market has published those parameters, the formulation and the label can be built to them rather than argued about.
| Market | What may be stated for the isoflavones | Regulatory basis | Priority for this ingredient |
| United States | A structure or function statement is a separate supplement pathway; the GRAS entry for this raw material covers flavoring use | 21 CFR 182.20; FEMA number 2326; FDA food substances database | Primary |
| European Union | No authorized claim for isoflavones or for red clover; the ingredient cannot carry a claim on its own account | EFSA opinion 2012; Regulation (EC) No 1924/2006; Commission Regulation (EU) No 432/2012 | Primary, with the constraint |
| Canada | Two conditional uses, with a stated dose range of 40 to 100 mg total aglycone isoflavone equivalents per day | Health Canada monograph, red clover isoflavone extract | Listed |
| Other markets | Not assessed here; the route has to be confirmed against the destination rules | - | To be confirmed per market |
What to Put on the Specification
A red clover isoflavones purchase goes wrong at the specification stage rather than at the delivery stage, and the fix is a short list of lines that have to be written rather than assumed.
| Line | What to write | Why it belongs there |
| Plant part | Dried flowering stems, leaves and inflorescence | The isoflavone profile belongs to the aerial parts |
| Standardization level | Total isoflavones as a percentage, at the grade ordered | Sets the starting point, not the answer |
| Basis | Total aglycone isoflavone equivalents, on a stated as-is or dried basis | Determines whether the figure can be used on a label |
| Individual markers | Formononetin, biochanin A, daidzein and genistein, each with a figure | Two lots at the same total can carry different marker sets |
| Assay method | HPLC | A certificate means nothing without the method |
| Particle size | Mesh pass rate, by weight | Drives blend uniformity and capsule fill weight |
| Loss on drying and ash | Limits, on a stated basis | Moisture dilutes every other figure |
| Heavy metals | Lead and arsenic, each with its own limit | One elemental line is not a specification |
| Microbiological panel | Total plate count, yeast and mold, and absence tests for E. coli and Salmonella | The buyer's own release will mirror these lines |
| Packaging and shelf life | Container type and stated shelf life | The loss on drying limit is set at delivery |
| Market and claim route | The destination market, and whether a claim is available there | Decides whether the label can carry a statement at all |
Frequently Asked Questions
Q: Does Red Clover Contain Isoflavones?
A: Yes. Red clover contains four isoflavones that matter commercially: formononetin, biochanin A, daidzein and genistein, with formononetin usually the highest of the four. The European Food Safety Authority names red clover alongside soy and kudzu root as a source of isoflavones, and Health Canada's monograph names the same four as the ones a label may declare next to the total.
Q: Red Clover Vs Soy Isoflavones: What Is The Difference?
A: They are different molecules. Red clover material is standardized on formononetin and biochanin A, while soy material is standardized on genistein, daidzein and glycitein. A specification written for one does not describe the other, so a formulation cannot be moved between them without redoing the dose basis and the label artwork.
Q: Is "20% Total Isoflavones" Enough To Describe A Specification?
A: No. The percentage does not say whether the glycoside forms were converted before the figures were added up. Health Canada's monograph states that adding aglycone and glycoside forms together overestimates the bioavailable quantity by almost a factor of two, so the specification has to state that the figure is expressed on a total aglycone isoflavone equivalent basis.
Q: What Side Effects And Contraindications Apply To Red Clover Isoflavones?
A: Health Canada's monograph contraindicates use in anyone with breast cancer or tumors, a predisposition indicated by an abnormal mammogram or biopsy, or a family member with breast cancer. It advises consulting a practitioner for users who are not up to date on mammograms and gynecological evaluations, those with a history of hormonal or gynecological disease, and those taking hormone replacement therapy, and it names breast pain, a recurrence of menstruation and uterine spotting as reactions that should stop use.
Q: Can A Red Clover Isoflavones Product Carry A Health Claim?
A: It depends entirely on the market, and in the European Union the answer for the isoflavones themselves is no. EFSA concluded in 2012 that the evidence was insufficient to establish a cause and effect relationship for bone mineral density and for menopausal vasomotor symptoms, and the authorized claims list contains no isoflavone or red clover entry. Canada permits two conditional uses instead.
Q: Which Grades Of Red Clover Extract Powder Are Traded?
A: Our product page lists 8%, 10%, 20% and 40% total isoflavones by HPLC, with 20% and 40% the grades most often bought in bulk, and a minimum order of 1 kg. Packaging is 25 kg fiber drums with double PE inner bags or 1 kg foil bags, and the stated shelf life is 24 months.
Next Step
A red clover isoflavones purchase comes down to four lines that a quotation cannot answer on its own: the plant part, the standardization level, the aglycone equivalent basis, and the market the label is being built for. Once those are written, quotations become comparable and the claim route becomes a decision rather than a discovery at artwork stage.
You can request a certificate of analysis, a technical data sheet and a sample through our inquiry form, or reach the documentation team through the contact page. The grades, markers and packaging options for red clover extract powder are listed on the product page, and buyers sourcing other natural ingredients can start from the category listing.
Sources
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590). EFSA Journal 2012;10(8):2847. https://www.efsa.europa.eu/en/efsajournal/pub/2847
- EFSA Panel on Food Additives and Nutrient Sources added to Food. Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones. EFSA Journal 2015;13(10):4246. https://www.efsa.europa.eu/en/efsajournal/pub/4246
- European Food Safety Authority. Isoflavones in food supplements for post-menopausal women: no evidence of harm. Press release, 21 October 2015. https://www.efsa.europa.eu/en/press/news/151021
- Health Canada. Monograph: Red Clover Isoflavone Extract. Natural and Non-prescription Health Products Directorate. https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=rcie&lang=eng&wbdisable=true
- US Food and Drug Administration. Substances Added to Food: Clover tops, red, extract solid (Trifolium pratense L.). https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=FoodSubstances&id=CLOVERTOPSREDEXTRACTSOLID
- Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health. https://www.legislation.gov.uk/eur/2012/432
- Regulation (EC) No 1924/2006 of the European Parliament and of the Council on nutrition and health claims made on foods. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32006R1924